In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence

Authors: Fred Arthur Zar,

Published: 2025-03-31

DOI: 10.7326/annals-25-00552-jc

Source: Full article

Abstract

No abstract found.